LB’s lead asset, LB-102, is a novel (patented) analog of amisulpride, a drug used in Europe for decades to treat schizophrenia and low-grade depression, designed to be more lipophilic.

In preclinical studies (ECNP 2017 ref) LB-102 was determined to be equivalent to amisulpride in: receptor binding and rodent PK profiles, and equivalent to or better than amisulpride in animal behavioral models of schizophrenia. In a Phase 1 study, LB-102 showed higher than expected plasma concentration compared to amisulpride and elicited EPS, a biomarker of > 80% dopamine receptor occupancy (mode of action) at lower than expected doses. A PET study in humans is expected to begin dosing in Q4.

Molecule
Preclinical
Phase 1
Phase 2
Phase 3
KarXT
Schizophrenia
LB-102
Schizophrenia
LB-102 LAI
Depression
LB-104
*Preclinically, LB is working on development of a long-acting form of LB-102 (impossible with amisulpride due to dose used) as well as LB-104 as a potential treatment for depression.